PLG and Parkinson disease: Additionally, clinical evidence from Sharma et al. (2021) demonstrated elevated levels of plasmin–antiplasmin complexes (PAP) in the plasma of PD patients, which is indicative of fibrinolytic system dysfunction in the disease [26].